{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:15:44Z","timestamp":1791515744220,"version":"4.3.4"},"reference-count":66,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81570148"],"award-info":[{"award-number":["81570148"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2019YFA0111000"],"award-info":[{"award-number":["2019YFA0111000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Municipal Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR1012B"],"award-info":[{"award-number":["SHDC2020CR1012B"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.isci.2025.113077","type":"journal-article","created":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T12:08:22Z","timestamp":1751890102000},"page":"113077","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A molecular-based risk score for predicting leukemia-free survival in adult AML patients undergoing Allo-HSCT"],"prefix":"10.1016","volume":"28","author":[{"given":"Shuang","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixian","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiong","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangbo","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaorui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiying","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongmei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0637-5324","authenticated-orcid":false,"given":"Xianmin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2025.113077_bib1","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms12475","article-title":"Genetic hierarchy and temporal variegation in the clonal history of acute myeloid leukaemia","volume":"7","author":"Hirsch","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2025.113077_bib2","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1038\/nature13038","article-title":"Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia","volume":"506","author":"Shlush","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.113077_bib3","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.isci.2025.113077_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1097\/MOH.0000000000000700","article-title":"Azacitidine maintenance in AML post induction and posttransplant","volume":"29","author":"Bewersdorf","year":"2022","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.isci.2025.113077_bib5","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.clml.2024.02.005","article-title":"Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant","volume":"24","author":"Ionescu","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.isci.2025.113077_bib6","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1097\/PPO.0000000000000573","article-title":"Checkpoint Inhibitors and Other Immune-Based Therapies in Acute Myeloid Leukemia","volume":"28","author":"Haddad","year":"2022","journal-title":"Cancer J."},{"key":"10.1016\/j.isci.2025.113077_bib7","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3324\/haematol.2022.280798","article-title":"New drugs before, during, and after hematopoietic stem cell transplantation for patients with acute myeloid leukemia","volume":"108","author":"Mohty","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2025.113077_bib8","first-page":"2173","article-title":"The use of prognostic models in allogeneic transplants: a perspective guide for clinicians and investigators","volume":"141","author":"Sorror","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.113077_bib9","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.113077_bib10","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1182\/blood-2014-01-552984","article-title":"Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation","volume":"123","author":"Armand","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.113077_bib11","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1182\/blood-2012-03-418202","article-title":"A disease risk index for patients undergoing allogeneic stem cell transplantation","volume":"120","author":"Armand","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.113077_bib12","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2164-16-S1-S5","article-title":"Next generation sequencing of acute myeloid leukemia: influencing prognosis","volume":"16","author":"Ilyas","year":"2015","journal-title":"BMC Genom."},{"key":"10.1016\/j.isci.2025.113077_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers11020252","article-title":"Next Generation Sequencing in AML-On the Way to Becoming a New Standard for Treatment Initiation and\/or Modulation?","volume":"11","author":"Leisch","year":"2019","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2025.113077_bib14","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1182\/blood-2009-07-235358","article-title":"Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet","volume":"115","author":"D\u00f6hner","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.113077_bib15","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.113077_bib16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","article-title":"Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN","volume":"140","author":"D\u00f6hner","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.113077_bib17","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/s41408-022-00764-9","article-title":"Prognostic impact of the AML ELN2022 risk classification in patients undergoing allogeneic stem cell transplantation","volume":"12","author":"Jentzsch","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2025.113077_bib18","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40164-024-00487-6","article-title":"Outcomes of acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation: validation, comparison and improvement of 2022 ELN genetic risk system","volume":"13","author":"Zhang","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.isci.2025.113077_bib19","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1038\/s41409-021-01450-3","article-title":"An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis","volume":"56","author":"Jimenez Jimenez","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.isci.2025.113077_bib20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-20735-1","article-title":"Prognostic prediction of novel risk scores (AML-DRG and AML-HCT-CR) in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation","volume":"12","author":"Cao","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2025.113077_bib21","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbmt.2019.09.006","article-title":"Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation","volume":"26","author":"Kongtim","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.isci.2025.113077_bib22","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/s41409-018-0344-9","article-title":"Impact of a novel prognostic model, hematopoietic cell transplant-composite risk (HCT-CR), on allogeneic transplant outcomes in patients with acute myeloid leukemia and myelodysplastic syndrome","volume":"54","author":"Kongtim","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.isci.2025.113077_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.103126","article-title":"Development and validation of a prognostic model for adult patients with acute myeloid leukaemia","volume":"62","author":"Ma","year":"2020","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2025.113077_bib24","series-title":"Comparing Hematopoietic Cell Transplant versus Other Treatments for Adults with Acute Myeloid Leukemia [Internet]","author":"Sorror","year":"2021"},{"key":"10.1016\/j.isci.2025.113077_bib25","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1038\/s41375-019-0494-9","article-title":"Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis","volume":"33","author":"Tachibana","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2025.113077_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2023.101533","article-title":"Cytogenetics and genomics of acute myeloid leukemia","volume":"37","author":"Snaith","year":"2024","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.isci.2025.113077_bib27","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1182\/asheducation-2016.1.348","article-title":"Mutations in AML: prognostic and therapeutic implications","volume":"2016","author":"DiNardo","year":"2016","journal-title":"Hematology."},{"key":"10.1016\/j.isci.2025.113077_bib28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1182\/blood-2014-11-610543","article-title":"Acute myeloid leukemia ontogeny is defined by distinct somatic mutations","volume":"125","author":"Lindsley","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.113077_bib29","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2025.113077_bib30","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","article-title":"Functional genomic landscape of acute myeloid leukaemia","volume":"562","author":"Tyner","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.isci.2025.113077_bib31","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","article-title":"Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials","volume":"116","author":"Grimwade","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.113077_bib32","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1002\/cncr.30567","article-title":"Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis","volume":"123","author":"Michelis","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.isci.2025.113077_bib33","doi-asserted-by":"crossref","first-page":"4075","DOI":"10.1182\/blood.V96.13.4075","article-title":"Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group\/Eastern Cooperative Oncology Group study","volume":"96","author":"Slovak","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.113077_bib34","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1038\/s41409-021-01255-4","article-title":"Prognostic impact of the adverse molecular-genetic profile on long-term outcomes following allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia","volume":"56","author":"Daher-Reyes","year":"2021","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.isci.2025.113077_bib35","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1038\/leu.2016.65","article-title":"Genetic alterations and their clinical implications in older patients with acute myeloid leukemia","volume":"30","author":"Tsai","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2025.113077_bib36","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.113077_bib37","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s43018-021-00213-9","article-title":"Hotspot DNMT3A mutations in clonal hematopoiesis and acute myeloid leukemia sensitize cells to azacytidine via viral mimicry response","volume":"2","author":"Scheller","year":"2021","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.isci.2025.113077_bib38","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1038\/leu.2011.342","article-title":"DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia","volume":"26","author":"Metzeler","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2025.113077_bib39","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.stemcr.2019.07.005","article-title":"Gata2 as a Crucial Regulator of Stem Cells in Adult Hematopoiesis and Acute Myeloid Leukemia","volume":"13","author":"Menendez-Gonzalez","year":"2019","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.isci.2025.113077_bib40","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1182\/bloodadvances.2023011554","article-title":"Linking GATA2 to myeloid dysplasia and complex cytogenetics in adult myelodysplastic neoplasm and acute myeloid leukemia","volume":"8","author":"Robbins","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2025.113077_bib41","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1159\/000525566","article-title":"A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations","volume":"145","author":"Desikan","year":"2022","journal-title":"Acta Haematol."},{"key":"10.1016\/j.isci.2025.113077_bib42","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/s41392-021-00870-3","article-title":"Activation of RAS\/MAPK pathway confers MCL-1 mediated acquired resistance to BCL-2 inhibitor venetoclax in acute myeloid leukemia","volume":"7","author":"Zhang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2025.113077_bib43","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1080\/10428194.2022.2116931","article-title":"Single and multiple point NRAS mutations in acute myeloid leukemia: a study of 327 well molecularly characterized patients","volume":"63","author":"Durinikova","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.isci.2025.113077_bib44","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1182\/bloodadvances.2022007168","article-title":"Impact of MRD status in patients with AML undergoing allogeneic stem cell transplantation in the first vs the second remission","volume":"6","author":"Jentzsch","year":"2022","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2025.113077_bib45","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1002\/jha2.260","article-title":"Impact of pretransplant mutation status on survival after allogeneic stem cell transplant for acute myeloid leukemia","volume":"2","author":"Selove","year":"2021","journal-title":"EJHaem"},{"key":"10.1016\/j.isci.2025.113077_bib46","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41408-017-0027-6","article-title":"Molecular predictors of post-transplant survival in acute myeloid leukemia","volume":"7","author":"Qin","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2025.113077_bib47","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1038\/s41409-019-0444-1","article-title":"Mutation clonal burden and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia and myelodysplastic syndromes","volume":"54","author":"Hamilton","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.isci.2025.113077_bib48","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/s41408-021-00471-x","article-title":"Prognostic relevance of remission and measurable residual disease status in AML patients prior to reduced intensity or non-myeloablative allogeneic stem cell transplantation","volume":"11","author":"Jentzsch","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.isci.2025.113077_bib49","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.jtct.2022.12.013","article-title":"An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia","volume":"29","author":"Tokaz","year":"2023","journal-title":"Transplant. Cell. Ther."},{"key":"10.1016\/j.isci.2025.113077_bib50","doi-asserted-by":"crossref","first-page":"3546","DOI":"10.1182\/blood.2021014520","article-title":"Impact of diagnostic genetics on remission MRD and transplantation outcomes in older patients with AML","volume":"139","author":"Murdock","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.113077_bib51","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1182\/bloodadvances.2020001904","article-title":"Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation","volume":"4","author":"Grimm","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2025.113077_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15041312","article-title":"Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation","volume":"15","author":"Jentzsch","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2025.113077_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24054790","article-title":"Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication","volume":"24","author":"Tiong","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.isci.2025.113077_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13092156","article-title":"The Impact of DNMT3A Status on NPM1 MRD Predictive Value and Survival in Elderly AML Patients Treated Intensively","volume":"13","author":"Heiblig","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.isci.2025.113077_bib55","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1182\/bloodadvances.2021004367","article-title":"Posttransplantation MRD monitoring in patients with AML by next-generation sequencing using DTA and non-DTA mutations","volume":"5","author":"Heuser","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2025.113077_bib56","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/s41409-023-01973-x","article-title":"Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation","volume":"58","author":"Kong","year":"2023","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.isci.2025.113077_bib57","doi-asserted-by":"crossref","first-page":"5091","DOI":"10.1182\/bloodadvances.2024013746","article-title":"Health-Related Quality of Life with Gilteritinib versus Placebo Post-Transplant for FLT3-ITD+ Acute Myeloid Leukemia","volume":"8","author":"Hamilton","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.isci.2025.113077_bib58","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1200\/JCO.22.00715","article-title":"Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia","volume":"41","author":"Grob","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.113077_bib59","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1200\/JCO.22.00181","article-title":"Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for TP53-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"40","author":"Mishra","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2025.113077_bib60","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00277-021-04734-2","article-title":"Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed\/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes","volume":"101","author":"Zeidan","year":"2022","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.isci.2025.113077_bib61","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed\/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.isci.2025.113077_bib62","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.isci.2025.113077_bib63","first-page":"156","article-title":"Early detection of bone marrow engraftment by amplification of hypervariable DNA regions","volume":"82","author":"Martinelli","year":"1997","journal-title":"Haematologica"},{"key":"10.1016\/j.isci.2025.113077_bib64","first-page":"825","article-title":"Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1994","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.isci.2025.113077_bib65","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.isci.2025.113077_bib66","series-title":"Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis","author":"Harrell","year":"2015"}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225013380?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004225013380?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T02:10:43Z","timestamp":1771380643000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004225013380"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":66,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2589004225013380"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2025.113077","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A molecular-based risk score for predicting leukemia-free survival in adult AML patients undergoing Allo-HSCT","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2025.113077","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"113077"}}